| Literature DB >> 30853252 |
Kirk M Chan-Tack1, Patrick R Harrington2, Su-Young Choi3, Laine Myers2, Julian O'Rear2, Shirley Seo3, David McMillan2, Hanan Ghantous2, Debra Birnkrant2, Adam I Sherwat2.
Abstract
The development and ultimate approval of tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the world for nearly 40 years, required a unique regulatory approach based on the US Food and Drug Administration's Animal Rule. We summarise the regulatory pathway and describe the challenges involved.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30853252 DOI: 10.1016/S1473-3099(18)30788-6
Source DB: PubMed Journal: Lancet Infect Dis ISSN: 1473-3099 Impact factor: 25.071